{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:27:46Z","timestamp":1785184066176,"version":"3.55.0"},"reference-count":18,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Methotrexate (MTX) is a disease-modifying drug used for psoriasis (PsO) and psoriatic arthritis (PsA), but dermatology and rheumatology guidelines differ in dosing and monitoring recommendations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>To compare methotrexate dosing and monitoring practices in dermatology and rheumatology, assess adverse drug reactions, and analyse the financial impact of rigorous monitoring.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This observational, electronic medical record-based retrospective chart review included psoriasis and psoriatic arthritis patients started on methotrexate at the dermatology and rheumatology departments at a tertiary care centre in 2020-2021. Patients with concurrent hepatotoxic\/myelotoxic medications, inadequate follow-up, or abnormal baseline laboratory tests were excluded. Data regarding demographics, relevant medical histories, clinical variables, methotrexate dosing, frequency of laboratory monitoring, adverse events, and resource utilization were recorded and analysed. Descriptive statistics (means\/percentages) and inferential tests (Chi-Square Test or Mann- Whitney Test) were used based on data normality (p&lt;0.05 considered significant).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The study included 100 psoriasis and psoriatic arthritis patients each. The psoriatic arthritis patients were given higher methotrexate doses initially but underwent less frequent laboratory monitoring compared to psoriasis patients. The incidence of hepatotoxicity was comparable between the two groups. However, leukopenia was observed more frequently in psoriatic arthritis patients. Methotrexate monitoring under dermatologists cost 44% more than that under rheumatologists over 6 months (Rs 4766.08\u00b1 1631.9 vs Rs 3290.32\u00b1 1207.8).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Limitations<\/jats:title>\n<jats:p>The single centre, small sample size, retrospective chart review, and convenience sampling in this study may all limit the generalisability of the findings.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Current methotrexate guidelines in dermatology recommend lower doses and more frequent monitoring than rheumatology guidelines. Insights from this study and comparison with rheumatology practices and existing literature highlight the potential for designing large-scale, multicentric, non-inferiority studies that could eventually help develop more efficient and streamlined methotrexate monitoring protocols for dermatology and rheumatology, ultimately improving patient adherence, safety and affordability.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_1384_2024","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T05:01:16Z","timestamp":1750482076000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Methotrexate dosage and laboratory monitoring in patients with psoriasis and psoriatic arthritis: A retrospective analysis of prescription patterns and financial impact in dermatology and rheumatology settings"],"prefix":"10.25259","volume":"0","author":[{"given":"Gopikrishnan","family":"Anjaneyan","sequence":"first","affiliation":[{"name":"Department of Dermatology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, All India Institute of Medical Sciences, Nagpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothish R","family":"Pillai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"CB","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekshmi","family":"Sajini","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Jagadeesan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinitha Varghese","family":"Panicker","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"10.25259\/IJDVL_1384_2024\/ref-1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"10.25259\/IJDVL_1384_2024\/ref-2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjd.14816","article-title":"British association of dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","volume":"175","author":"Warren","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_1384_2024\/ref-3","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint american academy of dermatology\u2013National psoriasis foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1384_2024\/ref-4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1384_2024\/ref-5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_1384_2024\/ref-6","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_1384_2024\/ref-7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jaad.2018.12.015","article-title":"Initiation of methotrexate with or without a test dose: A retrospective toxicity study","volume":"80","author":"Herrmann","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1384_2024\/ref-8","first-page":"1","article-title":"Methotrexate in psoriasis: Do we need to give a test dose?","volume":"103","author":"Carretero-Hern\u00e1ndez","year":"2012","journal-title":"ActasDermosifiliogr"},{"key":"10.25259\/IJDVL_1384_2024\/ref-9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2340\/00015555-2081","article-title":"Methotrexate dosing regimen for plaque-type psoriasis: A systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation","volume":"96","author":"Menting","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_1384_2024\/ref-10","doi-asserted-by":"publisher","first-page":"e0194401","DOI":"10.1371\/journal.pone.0194401","article-title":"Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines","volume":"13","author":"Busger Op Vollenbroek","year":"2018","journal-title":"PLoS One"},{"key":"10.25259\/IJDVL_1384_2024\/ref-11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.therap.2019.05.004","article-title":"Daily practices regarding safety monitoring of low-dose methotrexate and comparison to guidelines: A population-based cohort study","volume":"76","author":"Mazaud","year":"2021","journal-title":"Therapie"},{"key":"10.25259\/IJDVL_1384_2024\/ref-12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/1756-185X.12416","article-title":"Safety of less frequent monitoring of liver transaminases levels in rheumatic patients treated with low-dose methotrexate","volume":"17","author":"Khabbazi","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.25259\/IJDVL_1384_2024\/ref-13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s13555-023-00930-2","article-title":"Real-world experience of methotrexate in the treatment of skin diseases: An Italian delphi consensus","volume":"13","author":"Damiani","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_1384_2024\/ref-14","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2013 part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_1384_2024\/ref-15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/pde.15327","article-title":"Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines","volume":"40","author":"Siegfried","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"10.25259\/IJDVL_1384_2024\/ref-16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/ajd.12526","article-title":"Monitoring recommendations for oral azathioprine, methotrexate and cyclosporin in a paediatric dermatology clinic and literature review","volume":"59","author":"Yee","year":"2018","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_1384_2024\/ref-17","doi-asserted-by":"publisher","first-page":"e074678","DOI":"10.1136\/bmj-2022-074678","article-title":"Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: Prognostic model development and validation using primary care data from the UK","volume":"381","author":"Nakafero","year":"2023","journal-title":"BMJ"},{"key":"10.25259\/IJDVL_1384_2024\/ref-18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/09546634.2021.1937476","article-title":"Low-dose methotrexate in dermatology: The utility of serological monitoring in a real-world cohort","volume":"33","author":"Hajar","year":"2022","journal-title":"J Dermatol Treat"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/methotrexate-dosage-and-laboratory-monitoring-in-patients-with-psoriasis-and-psoriatic-arthritis-a-retrospective-analysis-of-prescription-patterns-and-financial-impact-in-dermatology-and-rheumatology\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/methotrexate-dosage-and-laboratory-monitoring-in-patients-with-psoriasis-and-psoriatic-arthritis-a-retrospective-analysis-of-prescription-patterns-and-financial-impact-in-dermatology-and-rheumatology\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T05:01:17Z","timestamp":1750482077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/methotrexate-dosage-and-laboratory-monitoring-in-patients-with-psoriasis-and-psoriatic-arthritis-a-retrospective-analysis-of-prescription-patterns-and-financial-impact-in-dermatology-and-rheumatology\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":18,"alternative-id":["10.25259\/IJDVL_1384_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1384_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"article-number":"1"}}